It is important to mention that preliminary pharmacodynamics and mechanistic biomarker analysis on pre- and post-treatment tumor NSCLC biopsies of patients (n=3) treated with adagrasib (phase 1/1b and 2) demonstrated down-regulation of KRAS/MAPK pathway genes, including DUSP6 and SPRY4 (53). This evidence concerns the gene KRAS and non-small cell lung carcinoma.